Intuitive Surgical consensus stays constructive, shares in NASDAQ 100 spotlight

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 11:22.

Intuitive Surgical (US46120E6023) sits firmly in the NASDAQ 100 as one of the larger U.S. medical technology names, with a market capitalization above 140 billion dollars according to recent price data from Hargreaves Lansdown.Hargreaves Lansdown quote overview Analyst services such as MarketBeat continue to show a predominantly Buy?tilted rating distribution and an average 12?month price target that implies upside from the current level.MarketBeat consensus for Intuitive Surgical

What the consensus numbers show

MarketBeat lists Intuitive Surgical with a consensus rating in the Buy range, based on more than a dozen recent analyst opinions that skew toward positive recommendations rather than Holds or Sells.MarketBeat consensus for Intuitive Surgical The same compilation reports an average analyst price target near 560 dollars per share, significantly above the roughly 400 dollar region where the shares last changed hands on Nasdaq on June 25, 2026.MarketBeat news and price data on ISRG

That target spread reflects expectations for solid growth in procedure volumes and recurring instrument revenue in the coming years, which together account for a substantial portion of Intuitive Surgical’s top line in the consensus models. According to MarketBeat, the implied upside from the current share price to the average target sits in the mid?double?digit percentage range, although individual houses show a wide dispersion between the lowest and highest targets.MarketBeat consensus for Intuitive Surgical

Recent ratings and sector context

Investor commentary collated by MarketBeat and other platforms indicates that several major Wall Street firms maintain positive stances on Intuitive Surgical, broadly in line with the constructive view Goldman Sachs recently expressed on the company’s fundamentals.Goldman?cited analysis on reuse debate and fundamentals The Goldman?referenced analysis points out that regulatory discussions about the reuse of surgical instruments are seen more as headline noise than a structural threat to the long?term business model, which underpins the bank’s supportive fundamental stance.Goldman?cited analysis on reuse debate and fundamentals

Within the broader U.S. medical technology and surgical robotics space, Intuitive Surgical competes with players such as Medtronic and Johnson & Johnson, yet still holds a leading installed base in minimally invasive robotic surgery systems according to industry commentators. The company’s inclusion in the NASDAQ 100 gives it additional visibility in index and ETF products that track U.S. large?cap growth and healthcare segments, which can influence daily trading volumes and ownership structures.Finanzen100 profile and index classification

The product behind the stock

Intuitive Surgical generates the bulk of its revenue with the da Vinci robotic surgery platform, a system used by hospitals worldwide to perform minimally invasive procedures across specialties such as urology, gynecology and general surgery. Each installed system creates a stream of recurring income from instruments, accessories and service contracts, which has historically given the company a resilient, high?margin business profile relative to many traditional medical device peers.Intuitive Surgical product overview for da Vinci systems

Where the shares trade today

The Intuitive Surgical shares (US46120E6023) last closed on Nasdaq at 399.69 US dollars on 2026-06-25 at 16:00 Eastern Time, with an after?hours indication around 401 to 402 dollars reported by MarketBeat.MarketBeat news and price data on ISRG

This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data and assessments are based on publicly available sources believed to be reliable but cannot be guaranteed for accuracy or completeness.